Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.…
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Altimmune (NASDAQ: ALT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 57 employees.
The shares were at 1.330 USD on 20 November 2026, down 67.6% over 52 weeks. Its 52-week range is 1.320 USD to 6.440 USD, and it trades at the bottom of that range.
Its market capitalisation is 258.80M USD.
Altimmune reports return on equity of -39.2%.
It holds more cash than debt, a net cash position of 228.86M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 4 March 2027.